Search results for: 'diagnostics data and alliances'

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to discovery-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Analyze co-development deals in pharma and biotech from 2016 to 2026. Includes financials, deal terms, and access to actual contracts where available.

Collaboration Deals in Pharmaceuticals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2020 to 2026

Cancer Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Track JV activity across pharma and biotech with real-world examples, financial terms, and partnering trends—includes access to contract documents where available.

Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2026

Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals.